Exosomes for regenerative medicine

Founded in 2012 by Duncan Ross, Ph.D., Kimera Labs has emerged as a game changer in the field of MSC exosome production and isolation. Unlike traditional biologic tissue laboratories that manufacture exosome products through direct processing of donor tissues such as adult bone marrow or placenta, Kimera Labs produces MSC exosomes from isolated mesenchymal stem cell cultures using chemically defined media, which is devoid of animal or human serum and adheres to FDA regulations. 

Utilizing advanced, proprietary exosome isolation technology, Kimera Labs creates the highest-purity MSC exosomes at scale, supporting the clinical development of novel, exosome-based therapeutic modalities. By harvesting, isolating, and purifying the developmental messages within exosomes produced by perinatal mesenchymal stem cells, we believe further studies will reveal their potential in regenerative medicine, particularly in enhancing patient outcomes in orthopedics and providing effective wound care solutions that can benefit individuals of all ages.

To provide the highest-quality clinical and research-grade MSC exosomes, Kimera Labs has made significant investments in Exosome Characterization and Quality Management, adhering to CGMP standards. This meticulous approach is a game changer in the field of regenerative medicine, particularly in orthopedics and wound care solutions, as it ensures the purity and consistency of each production line for improved patient outcomes. 

Kimera Labs confirms the quality of its exosomes through advanced characterization technologies, including ELISA protein analysis, high pressure liquid chromatography (HPLC), RNA sequencing, NanoSight Nano Tracking Analysis, Atomic Force Microscopy, Electron Microscopy, and STORM super resolution fluorescence microscopy. These strict production and characterization requirements are crucial for ensuring the consistent production of their exosome products, including pharmaceutical-grade MSC exosomes.

Kimera Labs continues to pursue advancements in MSC exosome production and the development of exosome-based diagnostics and therapeutics, operating in two adjacent state-of-the-art facilities featuring ISO 5 hoods and class 7 clean rooms. This innovative approach is a game changer in the field of regenerative medicine, particularly for improving patient outcomes in orthopedics and wound care solutions.

Kimera Labs produces MSC exosomes that harness the regenerative power of stem cells for future therapeutic applications without using the cells themselves. Utilizing a suite of advanced exosome characterization technology for the highest level of quality assurance, Kimera Labs is also profiling circulating exosomes present in injury and disease. This will pave the way for diagnostic modalities that allow earlier and more accurate detection than traditional tests. Post-doctoral scientific researchers at Kimera Labs collaborate closely with highly respected physicians and surgeons to design and develop new diagnostic and treatment modalities, including indication-specific engineered exosomes and optimized delivery systems for MSC exosomes.

As the leader in the field of MSC exosome research and development, Kimera Labs is dedicated to educating physicians and scientists alike to accelerate the advancement of exosome-based diagnostic and therapeutic modalities. This commitment is a game changer in regenerative medicine, especially in areas like orthopedics and wound care solutions, where improved patient outcomes are crucial. 

Being at the forefront of the exosome industry means setting standards that others will follow. However, confusion created by misleading claims can obscure progress and impede advancements in exosome technology. 

At our Kimera Labs campus, a 27,000 sq ft exosome production and research facility, visitors have the opportunity to learn about the latest scientific and clinical developments related to exosomes. They can see first-hand how MSC exosomes are produced and evaluated using the most sophisticated instrumentation available. 

Breakthroughs, the Kimera Labs newsletter, also serves as a reliable source of information about the evolution of the exosome industry and highlights Kimera Labs events and discoveries.

Our team of experienced researchers and medical professionals is dedicated to advancing the field of orthopedics and regenerative medicine. We bring a diverse range of skills and expertise to every project, focusing on game-changing wound care solutions that enhance patient outcomes.

We're always looking for game changer approaches in medical research, particularly in orthopedics. Our team is constantly exploring new technologies, techniques, and regenerative medicine strategies to enhance patient outcomes and develop effective wound care solutions.